Before Robert F. Kennedy Jr. was officially named health secretary, the impact of the Trump administration on U.S. health agencies was already significant. Key institutions like the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) faced severe challenges.
Many workers felt frightened, and this atmosphere of fear could change how the government operates. Holly Fernandez Lynch, a bioethicist and lawyer at the University of Pennsylvania, highlighted how this could harm public health. She noted, “If I were a virus, I’d see this as the perfect opportunity to disrupt health efforts.”
Lynch expressed deep concern about the “sledgehammer approach” taken against federal science and health programs. She believes such actions threaten American scientific progress for years to come, saying it’s shocking to consider how many potential medical advancements and cures may never materialize due to these cuts.
Recent developments paint a bleak picture. NIH funding for research grants was slashed, and on Friday, the Department of Health and Human Services, which includes the CDC, NIH, FDA, and others, announced it would lay off 5,200 new employees. This includes key figures like the director of the new Advanced Research Projects Agency for Health (ARPA-H), who were either let go or resigned unexpectedly.
This turmoil raises questions about the future of public health in the U.S. and the ability of these agencies to respond effectively to health crises. Without the right support, scientific research may suffer, impacting innovation and public health outcomes for years to come.
Source link
CDC,Donald Trump,Eli Lilly,FDA,HHS,NIH,Novo Nordisk,Pharmaceuticals,RFK Jr.,STAT+
